ACSS2 and neoplasm: In this paper, regarding ACSS2 mediating lipid metabolism, immune resistance, autophagy, and resistance to hypoxia to promote tumor growth, whether we can use ACSS2 inhibitors and in combination with some novel targeted inhibitors (such as lipid synthase inhibitor TVB-2640 [105]) to increase efficacy, and reducing the drug dosage and thus the drug side effects, need to be further studied.